A Phase 2 interventional study of MK0677 in Hip Fracture, sponsored by Merck Sharp & Dohme LLC. Terminated at 5 sites in 5 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2016-01-20.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Hip Fractures with a site in Germany — 1 open to participants now, 9 under way, none of them phase 3. Hip Fractures · Germany.
Among the 25 studies in Hip Fractures with a site in Germany, this one is the 14th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2005, is one of 4 in phase 2, and was the 2nd registered.
843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.
Browse Hip Fractures studies →1 of the 25 studies in Hip Fractures with a site in Germany is open now. Recruiting first, the newest first:
AgNovos Healthcare, LLC · Sites in Germany, Austria, Belgium and 8 more countries
Ages 65–91 · Women only
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 83 is close to the median of 86 across 534 interventional studies indexed under Hip Fractures.
Median enrollment 251 across the 16 interventional studies, 125 across the 9 observational. Of the 15 that completed or were terminated, 4 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 25 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 1 study filed under Hip Fractures — fewer than ten, so there is no comparison to draw.
4 of the studies in Hip Fractures with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04113044AO Innovation Translation CenterGo Fit Fast, Recovery Trajectory Using PROMIS®, Linking PROMIS® | 2026-12-31 |
| NCT04796350AgNovos Healthcare, LLCRESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures | 2027-04-01 |
| NCT05367505University of Witten/HerdeckeTitanium Fusion Implant in Combination With Trans-iliac Screws for Insufficiency Fractures of the Pelvis | 2027-06-07 |
| NCT04182776AO Innovation Translation CenterFragility Fractures of the Pelvis (FFP) | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 25 studies in Hip Fractures with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate an improvement in physical functional recovery, following administration of Drug for 24 weeks, in patients who have recently experienced a hip fracture. This study will also evaluate the safety and tolerability of Drug.
This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patient has Type II diabetes with any of conditions;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Proprietary Information - Exploratory (Non-Confirmatory) Trial
Proprietary Information - Exploratory (Non-Confirmatory) Trial
The record gives a start of Sep 2005, a primary completion of Aug 2007 and a completion of Aug 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibutamoren